Treatment-related toxicities in children with acute lymphoblastic leukaemia predisposition syndromes

European Journal of Medical Genetics

Volumn 59, Issue 12, 2016, Pages 654-660

  Schmiegelow, Kjeld ^a,b,c,d  

^a University of Copenhagen   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c Medicine and Oncology   (United States)

^d NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Acute lymphoblastic leukaemia; Child; Predisposition syndromes; Toxicity

Indexed keywords

TRANSCRIPTION FACTOR RUNX1; ANTINEOPLASTIC AGENT;

ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE TOXICITY; ARTICLE; ATAXIA TELANGIECTASIA; BLOOM SYNDROME; BONE MARROW DEPRESSION; CANCER EPIDEMIOLOGY; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; CHILDHOOD LEUKEMIA; DNA DAMAGE; DNA REPAIR; DNA STRUCTURE; DOWN SYNDROME; FAMILIAL CANCER; FANCONI ANEMIA; GENE MUTATION; GENETIC COUNSELING; GENETIC SCREENING; GERMLINE MUTATION; HUMAN; MISMATCH REPAIR; NIJMEGEN BREAKAGE SYNDROME; ONCOGENE K RAS; OVERALL SURVIVAL; PHENOTYPE; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SOMATIC MUTATION; TUMOR SUPPRESSOR GENE; WISKOTT ALDRICH SYNDROME; X LINKED AGAMMAGLOBULINEMIA; EXOME; GENETIC PREDISPOSITION; GENETICS; GENOTYPE; PATHOLOGY; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RISK FACTOR;

ANTINEOPLASTIC AGENTS; EXOME; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; GERM-LINE MUTATION; HUMANS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RISK FACTORS;

EID: 84959046349     PISSN: 17697212     EISSN: 18780849     Source Type: Journal    
DOI: 10.1016/j.ejmg.2016.02.006     Document Type: Article

References (87)

1. Albert, M.H., Notarangelo, L.D., Ochs, H.D., Clinical spectrum, pathophysiology and treatment of the Wiskott-Aldrich syndrome. Curr. Opin. Hematol. 18:1 (2011), 42–48.
2. Alter, B.P., Diagnosis, genetics, and management of inherited bone marrow failure syndromes. Hematology/the Education Program of the American Society of Hematology American Society of Hematology Education Program, 2007, 29–39.
3. Auer, F., Ruschendorf, F., Gombert, M., et al. Inherited susceptibility to pre B-ALL caused by germline transmission of PAX5 c. 547G > A. Leukemia 28:5 (2014), 1136–1138.
4. Auer, F., Ruschendorf, F., Gombert, M., et al. Reduced penetrance of inherited susceptibility to pre B-all caused by germline transmission of Pax5 C.547g > A. Haematologica, 99, 2014 11-.
5. Bache, I., Hasle, H., Tommerup, N., Olsen, J.H., Population-based study of cancer among carriers of a constitutional structural chromosomal rearrangement. Gene Chromosome Cancer 45:3 (2006), 231–246.
6. Bakry, D., Aronson, M., Durno, C., et al. Genetic and clinical determinants of constitutional mismatch repair deficiency syndrome: report from the constitutional mismatch repair deficiency consortium. Eur. J. Cancer 50:5 (2014), 987–996.
7. Bakry, D., Campbell, B., Durno, C., et al. Novel genetic and clinical determinants of constitutional mismatch repair deficiency syndrome: report from the CMMRD consortium. Cancer Res., 74(23), 2014.
8. Bienemann, K., Burkhardt, B., Modlich, S., et al. Promising therapy results for lymphoid malignancies in children with chromosomal breakage syndromes (Ataxia teleangiectasia or Nijmegen-breakage syndrome): a retrospective survey. Br. J. Haematol. 155:4 (2011), 468–476.
9. Bodo, S., Colas, C., Buhard, O., et al. Diagnosis of constitutional mismatch repair-deficiency syndrome based on microsatellite instability and lymphocyte tolerance to methylating agents. Gastroenterology 149 (2015), 1017–1029.
10. Bohnstedt, C., Levinsen, M., Rosthoj, S., et al. Physicians compliance during maintenance therapy in children with down syndrome and acute lymphoblastic leukemia. Leukemia 27:4 (2013), 866–870.
11. Bougeard, G., Renaux-Petel, M., Flaman, J.M., et al. Revisiting Li-Fraumeni syndrome from TP53 mutation carriers. J. Clin. Oncol. Official J. Am. Soc. Clin. Oncol. 33:21 (2015), 2345–2352.
12. Buitenkamp, T.D., Mathot, R.A., de Haas, V., Pieters, R., Zwaan, C.M., Methotrexate-induced side effects are not due to differences in pharmacokinetics in children with down syndrome and acute lymphoblastic leukemia. Haematologica 95:7 (2010), 1106–1113.
13. Buitenkamp, T.D., Izraeli, S., Zimmermann, M., et al. Acute lymphoblastic leukemia in children with down syndrome: a retrospective analysis from the Ponte di Legno study group. Blood 123:1 (2014), 70–77.
14. Camitta, B.M., Rock, A., Acute lymphoidic leukemia in a patient with thrombocytopenia/absent radii (Tar) syndrome. Am. J. Pediatr. Hematol. Oncol. 15:3 (1993), 335–337.
15. Caver, T.E., Slobod, K.S., Flynn, P.M., et al. Profound abnormality of the B/T lymphocyte ratio during chemotherapy for pediatric acute lymphoblastic leukemia. Leukemia 12:4 (1998), 619–622.
16. Cetiner, S., Demirhan, O., Inal, T.C., Tastemir, D., Sertdemir, Y., Analysis of peripheral blood T-cell subsets, natural killer cells and serum levels of cytokines in children with Down syndrome. Int. J. Immunogenet. 37:4 (2010), 233–237.
17. Chirnomas, S.D., Kupfer, G.M., The inherited bone marrow failure syndromes. Pediatr. Clin. N. Am. 60:6 (2013), 1291–1310.
18. Cohen, R.J., Curtis, R.E., Inskip, P.D., Fraumeni, J.F. Jr., The risk of developing second cancers among survivors of childhood soft tissue sarcoma. Cancer 103:11 (2005), 2391–2396.
19. Durno, C.A., Sherman, P.M., Aronson, M., et al. Phenotypic and genotypic characterisation of biallelic mismatch repair deficiency (BMMR-D) syndrome. Eur. J. Cancer 51:8 (2015), 977–983.
20. Felix, C.A., Hosler, M.R., Provisor, D., et al. The p53 gene in pediatric therapy-related leukemia and myelodysplasia. Blood 87:10 (1996), 4376–4381.
21. Frandsen, T.L., Heyman, M., Abrahamsson, J., et al. Complying with the European clinical trials directive while surviving the administrative pressure – an alternative approach to toxicity registration in a cancer trial. Eur. J. Cancer 50:2 (2014), 251–259.
22. Garre, M.L., Relling, M.V., Kalwinsky, D., et al. Pharmacokinetics and toxicity of methotrexate in children with down-syndrome and acute lymphocytic-leukemia. J. Pediatr US 111:4 (1987), 606–612.
23. Goldman, F.D., Gurel, Z., Al-Zubeidi, D., et al. Congenital pancytopenia and absence of B lymphocytes in a neonate with a mutation in the ikaros gene. Pediatr. Blood Cancer 58:4 (2012), 591–597.
24. Goldsby, R.E., Perkins, S.L., Virshup, D.M., Brothman, A.R., Bruggers, C.S., Lymphoblastic lymphoma and excessive toxicity from chemotherapy: an unusual presentation for Fanconi anemia. J. Pediatr. Hematol. Oncol. 21:3 (1999), 240–243.
25. Hasle, H., Olsen, J.H., Nielsen, J., Hansen, J., Friedrich, U., Tommerup, N., Occurrence of cancer in women with Turner syndrome. Br. J. Cancer 73:9 (1996), 1156–1159.
26. Hasle, H., Clemmensen, I.H., Mikkelsen, M., Risks of leukaemia and solid tumours in individuals with down's syndrome. Lancet 355:9199 (2000), 165–169.
27. Hedeland, R.L., Hvidt, K., Nersting, J., et al. DNA incorporation of 6-thioguanine nucleotides during maintenance therapy of childhood acute lymphoblastic leukaemia and non-Hodgkin lymphoma. Cancer Chemother. Pharmacol. 66:3 (2010), 485–491.
28. Heerema, N.A., Nachman, J.B., Sather, H.N., et al. Hypodiploidy with less than 45 chromosomes confers adverse risk in childhood acute lymphoblastic leukemia: a report from the children's cancer group. Blood 94:12 (1999), 4036–4045.
29. Hemminki, K., Chen, B., Familial association of leukemia with colorectal cancer. Leukemia Res. 28:10 (2004), 1113–1115.
30. Hersby, D.S., Sehested, A., Kristensen, K., Schmiegelow, K., T-cell all in ataxia telangiectasia cured with only 7 Weeks of Anti-leukemic therapy. J. Pediat Hematol. Oncol. 37:2 (2015), 154–155.
31. Holmfeldt, L., Wei, L., Diaz-Flores, E., et al. The genomic landscape of hypodiploid acute lymphoblastic leukemia. Nat. Genet. 45:3 (2013), 242–252.
32. Horgan, A.M., Yang, B., Azad, A.K., et al. Pharmacogenetic and germline prognostic markers of lung cancer. J. Thorac. Oncol. Official Publ. Int. Assoc. Study Lung Cancer 6:2 (2011), 296–304.
33. Hoshino, A., Okuno, Y., Migita, M., et al. X-linked agammaglobulinemia associated with B-precursor acute lymphoblastic leukemia. J. Clin. Immunol. 35:2 (2015), 108–111.
34. Hunger, S.P., Baruchel, A., Biondi, A., et al. The thirteenth international childhood acute lymphoblastic leukemia workshop report: La Jolla, CA, USA, December 7-9, 2011. Pediatr. Blood Cancer 60:2 (2013), 344–348.
35. Id Said, B., Malkin, D., A functional variant in miR-605 modifies the age of onset in Li-Fraumeni syndrome. Cancer Genet. 208:1–2 (2015), 47–51.
36. Izraeli, S., Vora, A., Zwaan, C.M., Whitlock, J., How I treat ALL in down's syndrome: pathobiology and management. Blood 123:1 (2014), 35–40.
37. Kalasekhar, V., Ranjith, S., Venkatesh, C., Bhat, B.V., Biswajith, D., Kayal, S., Dyskeratosis congenita with acute pre B cell lymphoblastic leukemia in a 10-year-old Girl. Indian J. Pediatr. 82:9 (2015), 867–868.
38. Kappel, S., Janschek, E., Wolf, B., et al. TP53 germline mutation may affect response to anticancer treatments: analysis of an intensively treated Li-Fraumeni family. Breast Cancer Res. Treat. 151:3 (2015), 671–678.
39. Kim, H., Yang, K., Dejsuphong, D., D'Andrea, A.D., Regulation of Rev1 by the Fanconi anemia core complex. Nat. Struct. Mol. Biol. 19:2 (2012), 164–170.
40. Kratz, C.P., Rapisuwon, S., Reed, H., Hasle, H., Rosenberg, P.S., Cancer in Noonan, Costello, cardiofaciocutaneous and LEOPARD syndromes. Am. J. Med. Genet. C 157C:2 (2011), 83–89.
41. Kratz, C.P., Franke, L., Peters, H., et al. Cancer spectrum and frequency among children with Noonan, Costello, and cardio-facio-cutaneous syndromes. Br. J. Cancer 112:8 (2015), 1392–1397.
42. Le, D.T., Uram, J.N., Wang, H., et al. PD-1 Blockade in tumors with mismatch-repair deficiency. New Engl. J. Med. 372:26 (2015), 2509–2520.
43. Letourneau, A., Santoni, F.A., Bonilla, X., et al. Domains of genome-wide gene expression dysregulation in down's syndrome. Nature 508:7496 (2014), 345–350.
44. Liew, E., Owen, C., Familial myelodysplastic syndromes: a review of the literature. Haematol Hematol J. 96:10 (2011), 1536–1542.
45. Locatelli, F., Niemeyer, C.M., How i treat juvenile myelomonocytic leukemia. Blood 125:7 (2015), 1083–1090.
46. Luczynski, W., Stasiak-Barmuta, A., Krawczuk-Rybak, M., Immunologic monitoring of maintenance therapy for acute lymphoblastic leukaemia in children-preliminary report. Pediatr. Blood Cancer 42:5 (2004), 416–420.
47. Lund, B., Asberg, A., Heyman, M., et al. Risk factors for treatment related mortality in childhood acute lymphoblastic leukaemia. Pediatr. Blood Cancer 56:4 (2011), 551–559.
48. Malkin, D., Nichols, K.E., Zelley, K., Schiffman, J.D., Predisposition to pediatric and hematologic cancers: a moving target. American Society of Clinical Oncology Educational Book/ASCO American Society of Clinical Oncology Meeting, 2014, e44–e55.
49. Mehta, P.A., Ileri, T., Harris, R.E., et al. Chemotherapy for myeloid malignancy in children with Fanconi anemia. Pediatr. Blood Cancer 48:7 (2007), 668–672.
50. Meyle, K.D., Guldberg, P., Genetic risk factors for melanoma. Hum. Genet. 126:4 (2009), 499–510.
51. Miething, C., Shah, S., Schrader, K., et al. Germline aberrations of PAX5 cause susceptibility to pre-B cell acute lymphoblastic leukemia. Onkologie, 36, 2013 52-.
52. Moriyama, T., Relling, M.V., Yang, J.J., Inherited genetic variation in childhood acute lymphoblastic leukemia. Blood 125:26 (2015), 3988–3995.
53. Nachman, J.B., Heerema, N.A., Sather, H., et al. Outcome of treatment in children with hypodiploid acute lymphoblastic leukemia. Blood 110:4 (2007), 1112–1115.
54. Noetzli, L., Lo, R.W., Lee-Sherick, A.B., et al. Germline mutations in ETV6 are associated with thrombocytopenia, red cell macrocytosis and predisposition to lymphoblastic leukemia. Nat. Genet. 47:5 (2015), 535–538.
55. Perez-Andreu, V., Roberts, K.G., Harvey, R.C., et al. Inherited GATA3 variants are associated with Ph-like childhood acute lymphoblastic leukemia and risk of relapse. Nat. Genet. 45:12 (2013), 1494–1498.
56. Perez-Andreu, V., Roberts, K.G., Xu, H., et al. A genome-wide association study of susceptibility to acute lymphoblastic leukemia in adolescents and young adults. Blood 125:4 (2015), 680–686.
57. Pollard, J.M., Gatti, R.A., Clinical radiation sensitivity with DNA repair disorders: an overview. Int. J. Radiat. Oncol. 74:5 (2009), 1323–1331.
58. Prucker, C., Attarbaschi, A., Peters, C., et al. Induction death and treatment-related mortality in first remission of children with acute lymphoblastic leukemia: a population-based analysis of the Austrian Berlin-Frankfurt-Munster study group. Leukemia 23:7 (2009), 1264–1269.
59. Pui, C.H., Mullighan, C.G., Evans, W.E., Relling, M.V., Pediatric acute lymphoblastic leukemia: where are we going and how do we get there?. Blood 120:6 (2012), 1165–1174.
60. Ram, G., Chinen, J., Infections and immunodeficiency in down syndrome. Clin. Exp. Immunol. 164:1 (2011), 9–16.
61. Richards, S., Pui, C.H., Gayon, P., Childhood Acute Lymphoblastic Leukemia Collaborative G. Systematic review and meta-analysis of randomized trials of central nervous system directed therapy for childhood acute lymphoblastic leukemia. Pediatr. Blood Cancer 60:2 (2013), 185–195.
62. Sandoval, C., Swift, M., Treatment of lymphoid malignancies in patients with ataxia-telangiectasia. Med. Pediatr. Oncol. 31:6 (1998), 491–497.
63. Schmiegelow, K., Vestergaard, T., Nielsen, S.M., Hjalgrim, H., Etiology of common childhood acute lymphoblastic leukemia: the adrenal hypothesis. Leukemia 22:12 (2008), 2137–2141.
64. Schmiegelow, K., Lausten Thomsen, U., Baruchel, A., et al. High concordance of subtypes of childhood acute lymphoblastic leukemia within families: lessons from sibships with multiple cases of leukemia. Leukemia 26:4 (2012), 675–681.
65. Schmiegelow, K., Levinsen, M.F., Attarbaschi, A., et al. Second malignant neoplasms after treatment of childhood acute lymphoblastic leukemia. J. Clin. Oncol. Official J. Am. Soc. Clin. Oncol. 31:19 (2013), 2469–2476.
66. Schulz, E., Valentin, A., Ulz, P., et al. Germline mutations in the DNA damage response genes BRCA1, BRCA2, BARD1 and TP53 in patients with therapy related myeloid neoplasms. J. Med. Genet. 49:7 (2012), 422–428.
67. Shah, S., Schrader, K.A., Waanders, E., et al. A recurrent germline PAX5 mutation confers susceptibility to pre-B cell acute lymphoblastic leukemia. Nat. Genet., 45(10), 2013 1226–U179.
68. Shah, A., John, B.M., Sondhi, V., Acute lymphoblastic leukemia with treatment–naive Fanconi anemia. Indian Pediatr. 50:5 (2013), 508–510.
69. Sorrell, A.D., Espenschied, C.R., Culver, J.O., Weitzel, J.N., Tumor protein p53 (TP53) testing and Li-Fraumeni syndrome: current status of clinical applications and future directions. Mol. Diagn. Ther. 17:1 (2013), 31–47.
70. Spinella, J.F., Healy, J., Saillour, V., et al. Whole-exome sequencing of a rare case of familial childhood acute lymphoblastic leukemia reveals putative predisposing mutations in Fanconi anemia genes. BMC Cancer, 15, 2015, 539.
71. Swann, P.F., Waters, T.R., Moulton, D.C., et al. Role of postreplicative DNA mismatch repair in the cytotoxic action of thioguanine. Science 273:5278 (1996), 1109–1111.
72. Talwalkar, S.S., Yin, C.C., Naeem, R.C., Hicks, M.J., Strong, L.C., Abruzzo, L.V., Myelodysplastic syndromes arising in patients with germline TP53 mutation and Li-Fraumeni syndrome. Arch. Pathol. Lab. Med. 134:7 (2010), 1010–1015.
73. Topka, S., Vijai, J., Walsh, M.F., et al. Germline ETV6 mutations confer susceptibility to acute lymphoblastic leukemia and thrombocytopenia. PLoS Genet., 11(6), 2015.
74. Trevino, L.R., Yang, W., French, D., et al. Germline genomic variants associated with childhood acute lymphoblastic leukemia. Nat. Genet. 41:9 (2009), 1001–1005.
75. Vang, S.I., Schmiegelow, K., Frandsen, T., Rosthoj, S., Nersting, J., Mercaptopurine metabolite levels are predictors of bone marrow toxicity following high-dose methotrexate therapy of childhood acute lymphoblastic leukaemia. Cancer Chemother. Pharmacol. 75:5 (2015), 1089–1093.
76. Villani, A., Tabori, U., Schiffman, J., et al. Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: a prospective observational study. Lancet Oncol. 12:6 (2011), 559–567.
77. Vlachos, A., Rosenberg, P.S., Atsidaftos, E., Alter, B.P., Lipton, J.M., Incidence of neoplasia in diamond blackfan anemia: a report from the diamond blackfan anemia registry. Blood 119:16 (2012), 3815–3819.
78. Waters, T.R., Swann, P.F., Cytotoxic mechanism of 6-thioguanine: hMutS alpha, the human mismatch binding heterodimer, binds to DNA containing S-6-methylthioguanine. Biochem. Us 36:9 (1997), 2501–2506.
79. Willig, T.N., Gazda, H., Sieff, C.A., Diamond-Blackfan anemia. Curr. Opin. Hematol. 7:2 (2000), 85–94.
80. Wimmer, K., Kratz, C.P., Constitutional mismatch repair-deficiency syndrome. Haematol Hematol J. 95:5 (2010), 699–701.
81. Wimmer, K., Kratz, C.P., Vasen, H.F., et al. Diagnostic criteria for constitutional mismatch repair deficiency syndrome: suggestions of the European consortium 'care for CMMRD' (C4CMMRD). J. Med. Genet. 51:6 (2014), 355–365.
82. Winther, J.F., Schmiegelow, K., How safe is a standard-risk child with ALL?. Lancet Oncol. 15:8 (2014), 782–783.
83. Winther, J.F., Sankila, R., Boice, J.D., et al. Cancer in siblings of children with cancer in the Nordic countries: a population-based cohort study. Lancet 358:9283 (2001), 711–717.
84. Wong, P., Han, K., Lack of toxicity in a patient with germline TP53 mutation treated with radiotherapy. Curr. Oncol. 21:2 (2014), e349–e353.
85. Xu, H., Zhang, H., Yang, W., et al. Inherited coding variants at the CDKN2A locus influence susceptibility to acute lymphoblastic leukaemia in children. Nat. Commun., 6, 2015, 7553.
86. Zhang, M.Y., Churpek, J.E., Kee, S.B., et al. Germ line ETV6 mutations in familial thrombocytopenia and hematologic malignancy. Nat. Genet. 47:2 (2015), 180–185.
87. Zhang, J., Walsh, M.F., Wu, G., et al. Germline mutations in predisposition genes in pediatric Cancer. N. Engl. J. Med., 2015.